1081 related articles for article (PubMed ID: 29174803)
1. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
Cai X; Wang X; Cao C; Gao Y; Zhang S; Yang Z; Liu Y; Zhang X; Zhang W; Ye L
Cancer Lett; 2018 Feb; 415():11-19. PubMed ID: 29174803
[TBL] [Abstract][Full Text] [Related]
2. HBXIP drives metabolic reprogramming in hepatocellular carcinoma cells via METTL3-mediated m6A modification of HIF-1α.
Yang N; Wang T; Li Q; Han F; Wang Z; Zhu R; Zhou J
J Cell Physiol; 2021 May; 236(5):3863-3880. PubMed ID: 33305825
[TBL] [Abstract][Full Text] [Related]
3. HBXIP promotes gastric cancer
Yang Z; Jiang X; Li D; Jiang X
Aging (Albany NY); 2020 Oct; 12(24):24967-24982. PubMed ID: 33048840
[TBL] [Abstract][Full Text] [Related]
4. The oncoprotein HBXIP enhances angiogenesis and growth of breast cancer through modulating FGF8 and VEGF.
Liu F; You X; Wang Y; Liu Q; Liu Y; Zhang S; Chen L; Zhang X; Ye L
Carcinogenesis; 2014 May; 35(5):1144-53. PubMed ID: 24464787
[TBL] [Abstract][Full Text] [Related]
5. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.
Hu N; Zhang J; Cui W; Kong G; Zhang S; Yue L; Bai X; Zhang Z; Zhang W; Zhang X; Ye L
J Biol Chem; 2011 Apr; 286(15):13714-22. PubMed ID: 21343296
[TBL] [Abstract][Full Text] [Related]
6. The oncoprotein HBXIP modulates the feedback loop of MDM2/p53 to enhance the growth of breast cancer.
Li H; Liu Q; Wang Z; Fang R; Shen Y; Cai X; Gao Y; Li Y; Zhang X; Ye L
J Biol Chem; 2015 Sep; 290(37):22649-61. PubMed ID: 26229107
[TBL] [Abstract][Full Text] [Related]
7. The oncoprotein HBXIP suppresses gluconeogenesis through modulating PCK1 to enhance the growth of hepatoma cells.
Shi H; Fang R; Li Y; Li L; Zhang W; Wang H; Chen F; Zhang S; Zhang X; Ye L
Cancer Lett; 2016 Nov; 382(2):147-156. PubMed ID: 27609066
[TBL] [Abstract][Full Text] [Related]
8. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
9. MiR-145-targeted HBXIP modulates human breast cancer cell proliferation.
Jiang Y; Wang D; Ren H; Shi Y; Gao Y
Thorac Cancer; 2019 Jan; 10(1):71-77. PubMed ID: 30381907
[TBL] [Abstract][Full Text] [Related]
10. N6-methyladenosine METTL3 promotes the breast cancer progression via targeting Bcl-2.
Wang H; Xu B; Shi J
Gene; 2020 Jan; 722():144076. PubMed ID: 31454538
[TBL] [Abstract][Full Text] [Related]
11. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
12. The oncoprotein HBXIP promotes glucose metabolism reprogramming via downregulating SCO2 and PDHA1 in breast cancer.
Liu F; Zhang W; You X; Liu Y; Li Y; Wang Z; Wang Y; Zhang X; Ye L
Oncotarget; 2015 Sep; 6(29):27199-213. PubMed ID: 26309161
[TBL] [Abstract][Full Text] [Related]
13. Displacement of Bax by BMF Mediates STARD13 3'UTR-Induced Breast Cancer Cells Apoptosis in an miRNA-Depedent Manner.
Guo X; Xiang C; Zhang Z; Zhang F; Xi T; Zheng L
Mol Pharm; 2018 Jan; 15(1):63-71. PubMed ID: 29179557
[TBL] [Abstract][Full Text] [Related]
14. BAG3-mediated miRNA let-7g and let-7i inhibit proliferation and enhance apoptosis of human esophageal carcinoma cells by targeting the drug transporter ABCC10.
Wu K; Yang Y; Zhao J; Zhao S
Cancer Lett; 2016 Feb; 371(1):125-33. PubMed ID: 26655271
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP uses two pathways to up-regulate S100A4 in promotion of growth and migration of breast cancer cells.
Liu S; Li L; Zhang Y; Zhang Y; Zhao Y; You X; Lin Z; Zhang X; Ye L
J Biol Chem; 2012 Aug; 287(36):30228-39. PubMed ID: 22740693
[TBL] [Abstract][Full Text] [Related]
16. The oncoprotein HBXIP activates transcriptional coregulatory protein LMO4 via Sp1 to promote proliferation of breast cancer cells.
Yue L; Li L; Liu F; Hu N; Zhang W; Bai X; Li Y; Zhang Y; Fu L; Zhang X; Ye L
Carcinogenesis; 2013 Apr; 34(4):927-35. PubMed ID: 23291272
[TBL] [Abstract][Full Text] [Related]
17. The oncoprotein HBXIP upregulates PDGFB via activating transcription factor Sp1 to promote the proliferation of breast cancer cells.
Zhang Y; Zhao Y; Li L; Shen Y; Cai X; Zhang X; Ye L
Biochem Biophys Res Commun; 2013 May; 434(2):305-10. PubMed ID: 23537647
[TBL] [Abstract][Full Text] [Related]
18. Deacetylation of tumor-suppressor MST1 in Hippo pathway induces its degradation through HBXIP-elevated HDAC6 in promotion of breast cancer growth.
Li L; Fang R; Liu B; Shi H; Wang Y; Zhang W; Zhang X; Ye L
Oncogene; 2016 Aug; 35(31):4048-57. PubMed ID: 26657153
[TBL] [Abstract][Full Text] [Related]
19. Essential role of METTL3-mediated m
Visvanathan A; Patil V; Arora A; Hegde AS; Arivazhagan A; Santosh V; Somasundaram K
Oncogene; 2018 Jan; 37(4):522-533. PubMed ID: 28991227
[TBL] [Abstract][Full Text] [Related]
20. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer.
Ouyang D; Hong T; Fu M; Li Y; Zeng L; Chen Q; He H; Wen Y; Cheng Y; Zhou M; Zou Q; Yi W
Breast Cancer Res; 2023 Feb; 25(1):19. PubMed ID: 36765397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
